ENTITY

PegBio (2565 HK)

36
Analysis
Health Care • China
PegBio Co., Ltd. is a biotechnology company focused on the discovery and development of innovative therapies for chronic diseases, particularly metabolic disorders. The company develops differentiated therapeutics for conditions such as type 2 diabetes mellitus, obesity, metabolic dysfunction-associated steatohepatitis (MASH), opioid-induced constipation (OIC), and congenital hyperinsulinemia. PegBio was founded in 2008 and is headquartered in Hangzhou, Zhejiang Province, China.
more
•05 May 2025 08:48

ECM Weekly (5 May 2025) - CATL, Chery, Ather, Drinda, Eco-Shop, Green Tea, DN Sol, Lotte Glo, Hanwha

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
700 Views
Share
bearish•PegBio
•30 Apr 2025 09:00

PegBio 派格生物 Pre-IPO: R&D Deceleration

​PegBio plans to raise up to $100m for a Hong Kong listing. We examined its latest prospectus and noted besides massive delays spotted in last PHIP...

Logo
475 Views
Share
bullish•BYD Company
•10 Mar 2025 08:25

ECM Weekly (10th Mar 2025) - BYD, Japan Post, Mixue, Sanhua, Chifeng, Nanshan, Goertek, Travel Food

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
737 Views
Share
bearish•PegBio
•04 Mar 2025 10:00

PegBio 派格生物 IPO: PHIP Updates Don’t Look Good

​PegBio plans to raise up to $100m for a Hong Kong listing. We compared the filings and noted massive delays and more competitors joining the race.

Logo
581 Views
Share
•17 Feb 2025 08:40

ECM Weekly (17th Feb 2025) - CATL, Hengrui, Mixue, Guming, Hexaware, Ajax, Aegis, Daiichi, Takasago

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
731 Views
Share
x